Lineage Cell Therapeutics (LCTX) Return on Sales (2016 - 2025)
Historic Return on Sales for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 0.93%.
- Lineage Cell Therapeutics' Return on Sales fell 1300.0% to 0.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.96%, marking a year-over-year decrease of 6600.0%. This contributed to the annual value of 1.96% for FY2024, which is 4500.0% up from last year.
- Per Lineage Cell Therapeutics' latest filing, its Return on Sales stood at 0.93% for Q3 2025, which was down 1300.0% from 6.99% recorded in Q2 2025.
- In the past 5 years, Lineage Cell Therapeutics' Return on Sales ranged from a high of 0.56% in Q4 2021 and a low of 9.7% during Q2 2021
- In the last 5 years, Lineage Cell Therapeutics' Return on Sales had a median value of 2.26% in 2023 and averaged 3.14%.
- Its Return on Sales has fluctuated over the past 5 years, first surged by 126900bps in 2021, then plummeted by -37000bps in 2023.
- Lineage Cell Therapeutics' Return on Sales (Quarter) stood at 0.56% in 2021, then plummeted by -493bps to 3.32% in 2022, then skyrocketed by 32bps to 2.26% in 2023, then skyrocketed by 50bps to 1.13% in 2024, then grew by 18bps to 0.93% in 2025.
- Its last three reported values are 0.93% in Q3 2025, 6.99% for Q2 2025, and 4.01% during Q1 2025.